ClinicalTrials.gg
RecruitingNCT07845929Updated Sep 29, 2026

Clinical Application of a Low-Dose CBCT AI Model

An interventional study of DeepPriorCBCT-V2 and Clinical standard protocol (Full-radiation-dose CBCT) in Cerebrovascular Diseases, Lung and Liver, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Cerebrovascular Disorders with a site in China — 41 open to participants now, 42 under way, 2 of them phase 3. Cerebrovascular Disorders · China.

Planned enrollment
8th of 53
1,380 · median 206
Started
2026
with 2 others
No phase
32 of 83
15 open now
Primary completion
2026-11
later than 18 of 41 live
Registered
82nd of 83
by date

Among the 83 studies in Cerebrovascular Disorders with a site in China, this one is the 8th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2026, is one of 32 with no phase, reaches primary completion later than 18 of the 41 other live ones, and was the 82nd registered.

Cerebrovascular Disorders

450 studies on the registry are indexed under Cerebrovascular Disorders; 127 are open to participants now.

Browse Cerebrovascular Disorders studies →

Open to participants now

41 of the 83 studies in Cerebrovascular Disorders with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 94 Cerebrovascular Disorders studies recruiting now, 54 (57%) set no upper age limit and 12 (13%) stop at 75 or younger; 9 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Cerebrovascular Disorders with a site in China, or all of them as a file.
02

Study summary

Cone Beam CT (CBCT) is an imaging modality used in interventional digital subtraction angiography (DSA). It produces three-dimensional images via cone-beam X-ray scanning and computer reconstruction. Clinically, CBCT guides puncture for pulmonary and hepatic lesions and evaluates post-intervention outcomes in liver cancer and cerebrovascular diseases. However, CBCT-guided interventions carry high patient radiation exposure; dose reduction often degrades image quality and impairs procedural results. Studies report that each 100 mGy radiation increment elevates cancer risk by 1.96-fold.

Artificial intelligence enables low-dose CBCT. Our prior DeepPriorCBCT model embedded anatomical priors using neural discrete representation learning, reducing thoracic CBCT dose to one-sixth of routine protocols while preserving image quality. We further developed DeepPriorCBCT-V2 using 55 000 pre-reconstruction CBCT datasets covering brain, thorax and abdomen. This multi-organ model maintains image quality at one-sixth standard radiation dose. Nevertheless, its real-world clinical performance remains unvalidated. We therefore designed this prospective multicenter randomized controlled trial to evaluate the clinical applicability of DeepPriorCBCT-V2.

03

Conditions studied

  • Cerebrovascular Diseases
  • Lung
  • Liver
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.

    • Requires CBCT-guided interventional treatment or surgery (e.g., cerebral angiography, lung puncture , hepatic artery chemoembolization, or percutaneous liver biopsy) and meets operational indications.

      • Can understand the study's purpose, procedures, potential risks, and benefits, and voluntarily signs a written form.

Exclusion criteria

Exclusion Criteria:

  • History of high-dose radiation exams or treatments.

    • Known allergies or severe adverse reactions to iodine contrast agents or other relevant medications.

      • Pregnant or breastfeeding women.

        • Severe comorbidities or chronic diseases (e.g., severe diabetes, renal insufficiency).

          • Severe mental illness or cognitive impairment preventing understanding of the study procedures or providing .

            ⑥ Participants are not suitable for the trial per investigator's opinion.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,380 participants (estimated)

Study arms

  • Experimental
    Participants will receive interventional procedures guided by DeepPriorCBCT-V2.

    Patients underwent interventional procedures guided by CBCT images reconstructed via the DeepPriorCBCT-V2 model from low-radiation-dose scans (1/6 of the conventional dose for the thorax and abdomen, and 1/5 for the brain).

    Other: DeepPriorCBCT-V2

  • Placebo comparator
    Participants will receive interventional procedures guided by clinical standard protocol.

    Patients underwent interventional procedures guided by CBCT images reconstructed via clinical standard protocol (full-radiation-dose).

    Device: Clinical standard protocol (Full-radiation-dose CBCT)

Interventions

  • OtherDeepPriorCBCT-V2

    Compared with conventional CBCT-guided interventional procedures and previously reported low-dose CBCT studies, the intervention adopted in the present study has several distinct advantages. First, most existing low-dose CBCT protocols only reduce radiation for a single anatomical region, mainly the thorax, while our DeepPriorCBCT-V2 model achieves stable low-dose reconstruction for the brain, thorax, and abdomen simultaneously, with radiation reduced to 1/6 of the standard clinical level for the thorax and abdomen and 1/5 for the brain. Second, unlike general noise-reduction algorithms used in previous studies, our model embeds anatomical prior information through neural discrete representation learning, which ensures consistent and reliable image quality at extremely low radiation doses without sacrificing intraoperative guidance accuracy. Third, this study is the first prospective multicenter randomized controlled trial to systematically verify the clinical feasibility of multi-orga

  • DeviceClinical standard protocol (Full-radiation-dose CBCT)

    Interventional procedures were performed under the guidance of clinical standard protocol (Full-radiation-dose CBCT).

06

What researchers measure

Primary outcomes

  1. Radiation dose

    Air Kerma (AK) refers to the sum of the initial kinetic energies transferred from uncharged ionizing radiation (such as X-ray photons) to charged particles in air, divided by the mass of air at that location.

    Time frame: Through study completion, an average of 5 months.

Secondary outcomes

  1. Operation time

    The time from the initiation to the completion of the interventional procedure.

    Time frame: Through study completion, an average of 5 months.

  2. Intraoperative complications.

    Procedure-related intraprocedural complications.

    Time frame: Through study completion, an average of 5 months.

  3. Post operative complications

    Procedure-related complications within 7 days after the interventional procedure.

    Time frame: Through study completion, an average of 5 months.

Other outcomes

  1. Subjective scoring

    Scoring of reconstructed CBCT images was performed by radiologists and interventional physicians using a 5-point Likert scale. The scale was defined as: 1 = very poor image quality; lesions cannot be assessed and the procedure cannot be guided; 2 = poor image quality; lesion assessment and procedure guidance are difficult; 3 = moderate image quality; lesion assessment is relatively difficult, but procedure guidance is feasible; 4 = good image quality; lesions can be assessed and procedure guidance is achievable; 5 = excellent image quality; lesion assessment is not compromised at all and procedure guidance is fully supported.

    Time frame: Through study completion, an average of 5 months.

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.

Of 96 non-industry interventional studies with no phase under Cerebrovascular Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 68. This study's planned 3 months is below that.

Counting every sponsor, half of 111 studies reached it within 30 months; a quarter within 14 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 29, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845929
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Aug 1, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 29, 2026

Study contacts

Lei Chen
Contact
chan0812@126.com
15971480677

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion